LBRX News & Events

LB Pharmaceuticals announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral investigational small molecule, is a potent and selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. Anna Eramo, Chief Medical Officer of LB Pharmaceuticals added, "We believe LB-102's pharmacologic profile, including selective D2, D3, and 5HT7 receptor antagonism and favorable tolerability observed in prior clinical trials, aligns well with the critical unmet needs in bipolar depression. Significant opportunity exists for new therapies that can offer early onset of effect, reduced side effects such as sedation and EPS (including akathisia), and improvement in anhedonia and cognitive deficits, all of which can impact a patient's ability to function."

LB Pharmaceuticals announced the appointment Dr. Minako Pazdera as General Counsel. Before joining LB Pharmaceuticals, Dr. Pazdera served as General Counsel and Corporate Secretary at Kardigan.

LB Pharmaceuticals announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. Prior to joining LB Pharmaceuticals, Ms. Rose served as Senior Vice President, Communications and Investor Relations at Lyell Immunopharma. Most recently Ms. Beaupre was the Chief Administrative Officer at Lyndra Therapeutics.